MOLLY WILLIS: Open Payments
NPI 1275921264 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$869 in 41 payments from 10 companies in 2025. Trend: 2023 $1,500 · 2024 $1,284 · 2025 $869
Food & beverage: $869
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 14 | $310 |
| E.R. Squibb & Sons, L.L.C. | 7 | $154 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $84 |
| Otsuka America Pharmaceutical, Inc. | 4 | $79 |
| Teva Pharmaceuticals USA, Inc. | 3 | $66 |
| Alkermes, Inc. | 3 | $54 |
| Janssen Pharmaceuticals, Inc | 2 | $37 |
| ABBVIE INC. | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Lundbeck LLC | 1 | $23 |
Products named: INGREZZA, COBENFY, CAPLYTA, UZEDY, ABILIFY ASIMTUFII, REXULTI, VIVITROL, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
